Alligator Bioscience AB Total Liabilities
Alligator Bioscience AB total liabilities. Based on the latest financial reports, Alligator Bioscience AB (ATORX) has total liabilities worth Skr61.79 Million SEK (≈ $6.65 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Alligator Bioscience AB liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Alligator Bioscience AB (2005–2025)
Total liabilities of Alligator Bioscience AB from 2005 to 2025. This chart illustrates how Alligator Bioscience AB's total liabilities have evolved over time, based on quarterly financial data. Explore Alligator Bioscience AB (ATORX) investment intensity to see how much of total assets are deployed in long-term investments.
Alligator Bioscience AB Competitors by Total Liabilities
The table below lists competitors of Alligator Bioscience AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Aethlon Medical Inc
NASDAQ:AEMD
|
USA | $1.04 Million |
|
Stelmine Canada Ltd
V:STH
|
Canada | CA$616.27K |
|
Rover Metals Corp
V:ROVR
|
Canada | CA$992.88K |
|
Metavisio (Thomson Computing)
PA:ALTHO
|
France | €45.52 Million |
|
Optiva Inc
TO:OPT
|
Canada | CA$134.78 Million |
|
Arctic Blue Beverages AB
ST:ARCTIC
|
Sweden | Skr22.39 Million |
|
Lithium One Metals Inc
V:LONE
|
Canada | CA$3.13 Million |
|
Ten Lifestyle Group PLC
LSE:TENG
|
UK | GBX25.26 Million |
Liability Composition Analysis (2005–2025)
This chart breaks down Alligator Bioscience AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ATORX asset base.
Liquidity & Leverage Metrics
Alligator Bioscience AB Total Liabilities Ratios Explained
Alligator Bioscience AB total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.58 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 18.57 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.95 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Alligator Bioscience AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Alligator Bioscience AB (2005–2025)
The table below shows the annual total liabilities of Alligator Bioscience AB from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr103.74 Million ≈ $11.16 Million |
-55.84% |
| 2024-12-31 | Skr234.93 Million ≈ $25.28 Million |
+120.39% |
| 2023-12-31 | Skr106.59 Million ≈ $11.47 Million |
+32.36% |
| 2022-12-31 | Skr80.53 Million ≈ $8.67 Million |
+58.13% |
| 2021-12-31 | Skr50.93 Million ≈ $5.48 Million |
+38.79% |
| 2020-12-31 | Skr36.69 Million ≈ $3.95 Million |
-30.28% |
| 2019-12-31 | Skr52.63 Million ≈ $5.66 Million |
+32.08% |
| 2018-12-31 | Skr39.85 Million ≈ $4.29 Million |
+58.89% |
| 2017-12-31 | Skr25.08 Million ≈ $2.70 Million |
+1.96% |
| 2016-12-31 | Skr24.59 Million ≈ $2.65 Million |
+27.52% |
| 2015-12-31 | Skr19.29 Million ≈ $2.08 Million |
-34.12% |
| 2014-12-31 | Skr29.27 Million ≈ $3.15 Million |
+221.31% |
| 2011-12-31 | Skr9.11 Million ≈ $980.49K |
+7.85% |
| 2010-12-31 | Skr8.45 Million ≈ $909.14K |
+21.24% |
| 2008-12-31 | Skr6.97 Million ≈ $749.87K |
+8.72% |
| 2007-12-31 | Skr6.41 Million ≈ $689.71K |
+0.39% |
| 2006-12-31 | Skr6.38 Million ≈ $687.02K |
-52.52% |
| 2005-12-31 | Skr13.45 Million ≈ $1.45 Million |
-- |
About Alligator Bioscience AB
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Belgium. The company develops Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 3 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, developed using N… Read more